Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Congming Wan is a traditional Chinese medicine (TCM) herbal formulation developed and marketed by Shaanxi Momentum Pharmaceutical (also known as Shaanxi Momentum Qixuehe Pharmaceutical). The formulation is based on a classical TCM prescription originally created by the Jin dynasty physician Li Dongyuan (1180-1251). It typically contains a blend of herbal ingredients including Cimicifuga rhizome, Pueraria root, Phellodendron bark, White Peony root, Vitex fruit, Codonopsis, Astragalus root, and Licorice root. Indicated for the treatment of blurred vision, deafness, and tinnitus, the product works according to TCM principles by benefiting qi to ascend yang and improving hearing and vision. It is an approved marketed product in China, administered as an oral pill.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Congming Wan.